Oji et al. reported that CML patients who had persistent BCR-ABL transcripts after imatinib were treated with HLA-A*24:02-restricted modified WT1 peptide vaccine every two weeks with imatinib, and a reduction in BCR-ABL mRNA was observed to the detection limit [97]. Here, WT1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.